Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

被引：0

作者：

不详

机构：

来源：

Drugs & Therapy Perspectives | 2007年 / 23卷 / 5期

关键词：

D O I：

10.2165/00042310-200723050-00001

中图分类号：

学科分类号：

摘要：

Disease-free survival improved and the risk of contralateral breast cancer decreased in postmenopausal women with hormone receptor-positive early breast cancer who switched to adjuvant exemestane after 2-3 years of tamoxifen to complete 5 years' adjuvant antiestrogen therapy relative to patients who continued tamoxifen. Exemestane and tamoxifen have different tolerability profiles, which offers some potential advantages and disadvantages. © 2007 Adis Data Information BV. All rights reserved.

引用

页码：1 / 4

页数：3

共 50 条

[1] Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen
Davies, C
[J]. CANCER TREATMENT REVIEWS, 2004, 30 (06) : 583 - 588
[2] Physical Activity and Survival of Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle Study
de Glas, Nienke A.
Fontein, Duveken B. Y.
Bastiaannet, Esther
Pijpe, Anouk
De Craen, Anton J. M.
Liefers, Gerrit-Jan
Nortier, Hans J. W. R.
de Haes, Hanneke J. C. J. M.
de Velde, Cornelis J. H. van
van Leeuwen, Flora E.
[J]. CANCER, 2014, 120 (18) : 2847 - 2854
[3] Comparison of cost of distant disease-free year gained of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
El Ouagari, K.
Karnon, J.
Kaura, S.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S104 - S104
[4] Comparison of the cost per distant disease-free year gained for upfront letrozole or anastrozole, or switched exemestane compared to tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: The UK perspective
Karnon, J.
di Trapani, F.
Kaura, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[5] Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer
不详
[J]. ONCOLOGY-NEW YORK, 2005, 19 (03): : 277 - +
[6] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
Gil J.M.
Rubio-Terrés C.
del Castillo-Saiz A.
González P.
Canorea F.
[J]. Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
[7] Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer
Boccardo, F.
[J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (02): : 76 - 77
[8] Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer
Francesco Boccardo
[J]. Nature Clinical Practice Oncology, 2008, 5 : 76 - 77
[9] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
Johnston, Stephen R. D.
[J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
[10] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu
Huiping Li
Zefei Jiang
Lin Gu
Jinhai Tang
Hui Xie
Yueyin Pan
Yunjiang Liu
Shude Cui
Xiaojia Wang
Li Cai
Yiqiong Zhang
Huadong Zhao
Zhimin Shao
[J]. Chinese Journal of Cancer Research, 2022, 34 (06) : 592 - 601

← 1 2 3 4 5 →